Seismic Therapeutic Announces Presentation of Preclinical Data for Advancing Novel Biologics Drug Programs at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies

Nine poster presentations support immunoglobin sculpting enzyme and dual-cell bidirectional antibody programs to control dysregulated adaptive immunity

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., the machine learning immunology company, today announced nine poster presentations supporting the company’s emerging pipeline of novel biologics derived from its proprietary IMPACT platform to treat autoimmune diseases at the 23rd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) taking place on June 20-23 in Boston, MA. Seismic’s immunoglobin (Ig) sculpting enzymes and dual-cell bidirectional (DcB) antibody programs will be highlighted in these presentations, demonstrating the design of therapeutics to address unmet medical needs for diseases involving dysregulation of humoral immunity and cell-mediated immunity, the two arms of the adaptive immune system. In particular, results from novel in vitro human assays to characterize inhibitory checkpoint receptor agonism will be presented along with activity readouts in in vivo humanized mouse models with Seismic’s lead DcB antibody program, in comparison to current benchmarks.

“We are thrilled to share preclinical data showing rapid advancement of our Ig sculpting enzymes and DcB antibody programs and highlighting the translational immunology capabilities within our IMPACT platform,” said Kevin Otipoby, PhD, Senior VP Immunology of Seismic Therapeutic. “There is a great need for optimized treatments of dysregulated adaptive immunity and our IMPACT platform enables us to efficiently design, optimize, and select novel biologics drug candidates to address acute and chronic autoantibody mediated diseases and cell-mediated autoimmune diseases.”

Details of the poster presentations at FOCIS 2023 are as follows:

DcB Antibody Programs

IMPACTing Autoimmunity Through Dual Targeting of Antigen Presenting Cells and T Cells via Inhibitory Receptor Agonism
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu139
Author: Stephanie Grebinoski, PhD

Identification and Characterization of Selective FcγRIIb Binders and their Potential of IMPACTing Immune-Mediated Diseases
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu133
Author: Stephen Lutz, BS

Identification and Characterization of Inhibitory Receptor Agonists for the Treatment of Autoimmune and Inflammatory Diseases
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu132
Author: Michael Cianci, MS

In vivo models supporting the identification of novel inhibitory receptor agonists for the treatment of immune-mediated diseases
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu130
Author: Minasri Borah, MS

Ig Sculpting Enzyme Programs

The Promise of Machine Learning: Using Seismic’s IMPACT Platform to Design IgG Cleaving Enzymes for Chronic Treatment of Autoimmune Diseases
Thursday, June 22^nd 7:30 a.m. -.7:30 p.m.
Poster number: Th143
Author: Alex Pellerin, PhD

In Vitro Assay Development to Assess Successful Removal of T and B Cell Epitopes Through Seismic’s IMPACT Platform
Wednesday, June 21^st 7:30 a.m. - 7:30 p.m.
Poster number: W138
Author: Andita Newton, MS

In Vivo PK/PD Assessment of Invisibilized IgG Cleaving Protease for Chronic Treatment of Autoimmune Diseases
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu142
Author: Liliana Sanmarco, PhD

Identifying Next Generation Ig Selective Cleaving Enzymes for Treatment of Autoimmune Diseases Using IMPACT Platform
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu134
Author: Purvi Mande, PhD

High-Throughput Western Blot for In Vitro and In Vivo Assessment of Human Ig Specific Cleaving Enzymes
Tuesday, June 20^th 6:00 - 7:45 p.m.
Poster number: Tu126
Author: Nam Le, BS

In addition to the poster presentations, Ivan Mascanfroni, PhD, Senior Director of Immunology at Seismic, will chair the “Adaptive Immunity” session on Friday, June 23^rd at 8 a.m.

About Dual-cell Bidirectional (DcB) Programs
Seismic’s DcB antibody approach targets dysregulated cell-mediated immunity by optimally engaging both T cells and antigen presenting cells, such as B cells, to restore homeostasis. Activating these pathways may control multiple diseases, such as multiple sclerosis, lupus and rheumatoid arthritis. DcB antibodies simultaneously engage multiple inhibitory pathways in more than one immune cell type thereby targeting and regulating both sides of the immune synapse.

About Immunoglobulin (Ig) Sculpting Programs
Seismic’s Ig sculpting enzymes address dysregulated humoral immunity by reducing both Ig levels and antibody effector functions, which contribute to the pathogenesis of a wide range of autoimmune diseases, such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and immune thrombocytopenia. Enzymes that specifically cleave antibodies may eliminate circulating and immune-complexed Ig, as well as cell surface B cell receptors, thereby modulating Ig-mediated autoimmunity and inflammation.

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow up on Twitter @Seismic_Tx and on LinkedIn.

Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com